diabetes
Avandia to face European safety review
July 12, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline’s type II diabetes drug Avandia, the subject of safety concerns since its launch in 2000, is to be reviewed …
Avandia probe deepens
June 29, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline has come under further scrutiny from the FDA after two new studies showed patients taking its troubled diabetes medication …
Boehringer cheered by diabetes data
June 28, 2010Research and Development Boehringer, DPP-4, diabetes, linagliptin
Boehringer Ingelheim has been cheered by phase III data showing its new oral once-daily type II diabetes tablet linagliptin significantly …
Sanofi licences novel oral anti-diabetic treatment
June 25, 2010Research and Development, Sales and Marketing Metabolex, Sanofi-Aventis, diabetes
Sanofi-Aventis has signed an exclusive worldwide licensing agreement with US-based diabetes specialist Metabolex for a novel oral anti-diabetic treatment. MBX-2982 …
Digital Pharma: Playing healthcare games
June 23, 2010Medical Communications Boehringer, Novartis, diabetes, digi game, malaria, virtual games
Boehringer Ingelheim has become the latest pharma company to use an online game to raise disease awareness. The pharma company …
Victoza wins partial NICE recommendation
June 15, 2010Sales and Marketing NICE, Victoza, diabetes
Novo Nordisk has been given a limited approval for its new type II diabetes treatment in draft guidance issued by …
Lixisenatide scores in phase III trial
April 15, 2010Research and Development GLP-1, Lixisenatide, diabetes
Sanofi-Aventis’ novel, once-daily diabetes treatment lixisenatide has successfully met its phase III glucose blood level and glycaemic control endpoints. The …
Roche buys insulin patch company
April 13, 2010Research and Development Diagnostics, Roche, diabetes
Roche has acquired insulin delivery specialist company Medingo to consolidate its presence in the diabetes care market. Medingo, formerly a …
Sanofi-Aventis signs drug with potential to reverse diabetes
April 9, 2010Research and Development Sanofi, diabetes
Sanofi-Aventis has signed a deal with a US biotech firm to develop a new treatment which could restore patients’ ability …
Five-year cardiovascular study planned for Onglyza
March 10, 2010Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
Stem cell therapy helps diabetes limb problems
March 3, 2010Research and Development ReNeuron, diabetes, stem cell
Stem cell therapy aimed at restoring blood flow to damaged limbs in people with diabetes has shown promise, according to UK …
GSK hits back at Avandia safety probe
February 25, 2010Sales and Marketing Avandia, diabetes
GlaxoSmithKline has hit back at allegations from US Senators that its diabetes drug Avandia raises the risk of heart attacks, …
Reports raise fresh Avandia safety questions
February 23, 2010Research and Development, Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline’s troubled diabetes drug Avandia has been hit by fresh reports from the US that it increases the risk of …
Roche diabetes trial proves promising
February 11, 2010Research and Development GLP-1, Roche, diabetes, taspoglutide
Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …
Lilly signs diabetes deal with Alizé Pharma
February 2, 2010Research and Development Alize, diabetes, lilly, type II
Lilly has signed a new research and licensing deal with Lyon-based Alizé Pharma to develop Alizé’s AZP-01 programme, focused on …
Latest content
